Cited by 587Liver Disease Diagnosis and TreatmentLiver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer

Open access

Tsuchida, Takuma, Lee, Youngmin A., Fujiwara, Naoto, Ybanez, Maria, Allen, Brittany, Martins, Sebastiao, Fiel, M. Isabel, Goossens, Nicolas, Chou, Hsin-I., Hoshida, Yujin, Friedman, Scott L.·2018·Journal of Hepatology

DOI 10.1016/j.jhep.2018.03.011PMC PMC6054570

Open this paper in CoChat — free account

Abstract

Background and Aims Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.03.011

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citation
IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis
Maeda, S., Kamata, H., Luo, J., Leffert, H. L., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,160

Show all 56 references

Sorted by citations

Items 401–500 of 587

Resolvin D1-mediated cellular crosstalk protects against MASH
Navarro‐Corcuera, A., Zhu, Y., Ma, F., Gupta, N., Asplund, H., Cogliati, B., Chipuk, J. E., Rom, O., Friedman, S. L., Sansbury, B. E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101454 · Cited by 7
Self-citation
Long non-coding RNA-EN_181 potentially contributes to the protective effects of N-acetylcysteine against non-alcoholic fatty liver disease in mice
Yang, W., Guo, R., Pi, A., Ding, Q., Hao, L., Song, Q., Chen, L., Dou, X., Na, L., & Li, S. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114522001829 · Cited by 4
Choline-deficient Diet-induced NAFLD Animal Model Recaptures Core Human Pathophysiology With Similar Gene Co-expression Networks
Ishigure, T., Sasase, T., Tohma, M., Uno, K., Toriniwa, Y., Saito, T., Saigo, Y., Edamura, K., Miyajima, K., & Ohta, T. (2023) · In Vivo · doi:10.21873/invivo.13237 · Cited by 6
An Efficient Model of Non-alcoholic Fatty Liver Disease (NAFLD) Versus Current Experimental Models: Effects of Fructose, Fat, and Carbon Tetrachloride on NAFLD
Eslami, Z., Mirghani, S. J., Moghanlou, A. E., Norouzi, A., Naseh, H., Joshaghani, H., Peres, W. A. F., Younesian, O., Hosseinzadeh, S., & Bideskan, J. A. (2021) · Hepatitis Monthly · doi:10.5812/hepatmon.117696 · Cited by 5
Group 2 innate lymphoid cells constrain type 3/17 lymphocytes in shared stromal niches to restrict liver fibrosisPreprint
Sbierski‐Kind, J., Cautivo, K. M., Wagner, J. C., Dahlgren, M. W., Nilsson, J., Krasilnikov, M., Mroz, N. M., Lizama, C. O., Gan, A. L., Matatia, P. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.26.537913 · Cited by 5
Mannose Supplementation Curbs Liver Steatosis and Fibrosis in Murine MASH by Inhibiting Fructose MetabolismPreprint
Hong, J. G., Carbajal, Y., Trotman, J. C., Glass, M., Sclar, V., Alter, I. L., Zhang, P., Wang, L., Chen, L., Petitjean, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576067 · Cited by 4
Self-citation
Dual neovascular targets of vascular endothelial growth factor receptors and platelet‐derived growth factor receptor ameliorate thioacetamide induced liver fibrosis in rats
Xiong, B., Bai, Y., Liu, J., Li, T., Wang, Y., & Zhou, C. (2024) · Portal hypertension & cirrhosis · doi:10.1002/poh2.75 · Cited by 3
Butein Alleviates Non-Alcoholic Steatohepatitis in Leptin-Deficient Mice by Modulating the PDE4/cAMP/p-CREB Pathway
Guo, C., Zhang, Y., Xue, H., Zhao, X., Wang, B., Deng, L., Zhu, X., Zhang, X., Zhang, Y., & Liu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s530855 · Cited by 3
The Proteomic Profiling of Circulating Extracellular Vesicles of Western Diet and Chemical‐Induced Murine MASH Model
Wang, S., Wang, Y., Huang, J., Lin, E., Chen, W.-S., Li, C., Dai, C., Chuang, W., Yu, M., & Wang, S. (2025) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70107 · Cited by 3
The progression of metabolic dysfunction-associated steatotic liver disease toward hepatocellular carcinoma in an efficient rat model
Márquez-Quiroga, L. V., Cardoso-Lezama, I., Alarcón‐Sánchez, B. R., Gaitán-González, P., Idelfonso-García, O. G., Vargas-Pozada, E. E., Piña‐Vázquez, C., Ramos‐Tovar, E., Villa‐Treviño, S., Arellanes‐Robledo, J., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117369 · Cited by 4
Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis
Zhou, Z., Luo, Z., Lv, X., Chen, L., Qin, Z., Ma, Q., Zheng, L., & Kong, D. (2025) · BMC Chemistry · doi:10.1186/s13065-025-01630-y · Cited by 3
Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Liang, Z., Chen, L., Liao, Z., Mao, J., Liu, Y., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01825 · Cited by 3
Modulation of Gut Microbes and Hepatic Metabolites by PCP Ameliorates NASH and Fatigue-like Performance in Mice
Hong, Y., Yang, J., Wang, Y., Chen, D., Wu, A., Li, M., Ou, W., Lin, G., Lin, C., & Liang, Y. (2025) · Nutrients · doi:10.3390/nu17233797 · Cited by 3
ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma
Zhu, Q., Gu, Y., Gao, Y., Zhao, X., & Zhang, L. (2025) · Autophagy · doi:10.1080/15548627.2025.2601035 · Cited by 3
From mechanisms to anti-fibrotic drugs in hepatic stellate cell research: a global bibliometric analysis with patent and clinical perspectives (2000–2025)
Mao, X., Chen, P., Wubur, P., Liu, Y., Zhao, Y., Zhang, S., Guan, N., & Li, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1734449 · Cited by 6
Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast niches
Sbierski‐Kind, J., Cautivo, K. M., Nilsson, J., Wagner, J., Dahlgren, M. W., Ewing-Crystal, N. A., Krasilnikov, M., Mroz, N. M., Ganslmeier, M., Lizama, C. O., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea6805 · Cited by 3
Role of miRNA signalling in the pathogenesis of MASLD
Cheng, S., Hao, J., & Qin, H.-Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1756805 · Cited by 3
Comparison and Characteristics of MASLD Mouse Models
Wei, L., 高春辰, & Qin, H. (2026) · Biomedicines · doi:10.3390/biomedicines14040895 · Cited by 3
Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model
Honda, A., Kamata, S., Tanaka, R., Minomo, Y., Ino, S., Kamichatani, W., Hishiki, T., Akahoshi, N., Nakagawa, S., Nunomura, K., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119432 · Cited by 3
Experimental Rodent Models of Metabolic Dysfunction-Associated Fatty Liver Disease: Present Status and Future Perspective
Bhopale, K. K., & Srinivasan, M. P. (2026) · Livers · doi:10.3390/livers6030045 · Cited by 3
Alleviative effects of fibroblast growth factor 21 on fibrogenic genes expression in the fructose activated hepatic stellate cells, an in vitro study
Shakerian, E., Yaghooti, H., Kheirollah, A., & Mohammadtaghvaei, N. (2022) · Immunopathologia Persa · doi:10.34172/ipp.2022.29268 · Cited by 3
Co-targeting ASK1 and THRβ synergistically improves steatohepatitis and fibrosis in a MASH animal model
Shang, S., Wan, Q., Chen, F., & Hu, J. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149739 · Cited by 3
Advances in the study of the mechanism of action of miR‑22 in liver lesions (Review)
Wang, M., Wang, X., Wang, Y., Gai, Y., Ye, J., Xu, X., & You, X. (2024) · Oncology Letters · doi:10.3892/ol.2024.14674 · Cited by 3
Design, synthesis and biological evaluation of Alisol B derivatives for potential treatment of non-alcoholic steatohepatitis
Yu, N.-R., Huang, S., Deng, Z., Wang, J., Shen, Y., Leng, Y., & Zhao, Q. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108132 · Cited by 3
Deletion of H-ferritin in macrophages mitigates the development of steatohepatitis and hepatocellular carcinoma in mice
Ikeda, Y., Funamoto, M., Itami, H., Yamamoto, M., Du, L. N. H., Imanishi, M., & Tsuchiya, K. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00328.2024 · Cited by 3
Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver disease
Yiğit, B., Özgönül, E., Yaman, O., Sipahioglu, T., Ulukan, B., Taş, Y. Ç., Morova, B., Aydın, M., Uysallı, Y., Demirtas, E., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98680-y · Cited by 3
Oxy210 Inhibits Hepatic Expression of Senescence-Associated, Pro-Fibrotic, and Pro-Inflammatory Genes in Mice During Development of MASH and in Hepatocytes In Vitro
Wang, F., Hui, S. T. Y., Stappenbeck, F., Kamińska, D., Lusis, A. J., & Parhami, F. (2025) · Cells · doi:10.3390/cells14151191 · Cited by 4
The Potential Effect of Intestinal Flora and Metabolites on High-Fat Diet-Mediated Nonalcoholic Fatty Liver Disease
韩, 志. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125700 · Cited by 3
Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma
Green, C. D., & Spiegel, S. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100925 · Cited by 3
A fast and accurate mouse model for inducing non-alcoholic steatohepatitis.
Rahimi, S., Angaji, S. A., Majd, A., Hatami, B., & Baghaei, K. (2022) · Gastroenterology and hepatology from bed to bench. · doi:10.22037/ghfbb.v15i4.2593 · Cited by 4
New murine model of alcoholic hepatitis in obesity-induced metabolic-associated fatty liver disease
Cheng, Y., Lin, S., Ren, T., Zhang, J., Shi, Y., Chen, Y., & Chen, Y. (2023) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0160 · Cited by 3
The Impact and Mechanism of TET3 Overexpression on the Progression of Hepatic Fibrosis
Liu, R., Feng, L., Tang, S., Liu, Y., & Yang, Q. (2023) · Epigenomics · doi:10.2217/epi-2023-0146 · Cited by 3
The Current Proceedings of PSC-Based Liver Fibrosis Therapy
Li, M., Wu, Q., & Tam, P. K. H. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10592-4 · Cited by 3
Quantitative assessment of inflammation and evaluation of spatial heterogeneity for non-alcoholic fatty liver disease in mice based on iron-adjustive T1
Li, L., Liao, B., Cai, H., Zhang, Y., Deng, K., Chen, Y., Chen, M., Zhou, X., Tang, M., Dong, Z., et al. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-782 · Cited by 3
Tumor-Extrinsic Axl Expression Shapes an Inflammatory Microenvironment Independent of Tumor Cell Promoting Axl Signaling in Hepatocellular Carcinoma
Breitenecker, K., Heiden, D., Demmer, T., Weber, G., Primorac, A.-M., Hedrich, V., Ortmayr, G., Gruenberger, T., Starlinger, P. P., Herndler‐Brandstetter, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084202 · Cited by 3
Isovalerylspiramycin I alleviates liver injury and liver fibrosis by targeting the nucleotide-binding protein 2 (NUBP2)-vascular non-inflammatory molecule-1 (VNN1) pathway
Zhang, N., Niu, W., Niu, W., Li, Y., Guo, S., Li, Y., He, W., & He, H. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101048 · Cited by 3
Complement 3a receptor 1 on macrophages and Kupffer cells is not required for the pathogenesis of metabolic dysfunction-associated steatotic liver diseasePreprint
Homan, E. A., Gilani, A., Rubio‐Navarro, A., Johnson, M. A., Schaepkens, O. M., Cortada, È., de Lima, R. P., Stoll, L., & Lo, J. C. (2024) · eLife · doi:10.7554/elife.100708 · Cited by 3
Protective effects of dopamine against non-alcoholic steatohepatitis via inhibiting p65 pathways in vivo and in vitro
Ma, P., Wang, X., Wen, X., Pu, L., & Ou, Y. (2024) · Toxicology Research · doi:10.1093/toxres/tfae068 · Cited by 2
Syringa pubescens Turcz. ethyl acetate extract improves non-alcoholic steatohepatitis by regulating the Nrf2, IκBα and TGF-β1 signaling pathways
Xu, W., Wu, Y., Xiong, J., Zhang, J., Zhang, Z., Guan, X., Zhang, S., Wang, X., Liu, P., & Fan, E. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250244 · Cited by 2
Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model
Chiu, V., Yee, C., Main, N., Stevanovski, I., Watt, M. J., Wilson, T., Angus, P., Roberts, T. L., Shackel, N. A., & Herath, C. B. (2024) · Clinical Science · doi:10.1042/cs20240560 · Cited by 2
Soluble Siglec-9 Improves Intestinal Barrier Function in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis
Muto, H., Mizuno, F., Honda, T., Yokoyama, S., Tanaka, T., Yamamoto, K., Ito, T., Imai, N., Ishizu, Y., Sakai, K., et al. (2025) · Metabolites · doi:10.3390/metabo15060366 · Cited by 2
Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis
Adams, J. A., Zhang, Y., Sun, J., Tilston-Lünel, A., Higgins, C. B., Heitmeier, M. R., Ballentine, S. J., Tycksen, E., Dolle, R. E., Hruz, P. W., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000810 · Cited by 2
The critical role of methylenetetrahydrofolate dehydrogenases in immune regulation and auto-immunity
Bunyard, P., Makrecka‐Kuka, M., & McMillan, L. (2025) · Journal of Inflammation · doi:10.1186/s12950-025-00469-3 · Cited by 2
O ‐GlcNAc Transferase Promotes Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Hepatocellular Carcinoma by Facilitating the Degradation of PTEN
Liu, H., Pu, S., Zhu, W., Huang, J., & Li, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70042 · Cited by 2
Role of the Plasminogen Activation System in Liver Injury and Repair: Knowns and Known Unknowns
Banerjee, D., Wei, Z., & Luyendyk, J. P. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.321606 · Cited by 2
Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models
Wang, Z., Naruse, K., & Takahashi, K. (2026) · Pathophysiology · doi:10.3390/pathophysiology33010010 · Cited by 3
Seipin expression in hepatocytes impairs the assembly of VLDLs and exacerbates steatohepatitis
Dong, Q., Ma, Y., Chen, X., Wang, X., Liu, Z., Liang, C., Qiu, L., Jinye, T., Wu, J., Liu, Y., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.100988 · Cited by 2
Bioengineered Exosome‐Loaded Immunomodulatory Bioadhesive Spray Reverses Liver Fibrosis and Metabolic Dysfunction That Triggers Beneficial Gut‐Liver Crosstalk in Chronic Fatty Liver Disease
Saha, T., Mairal, A., Mehrotra, S., Sarin, S. K., & Kumar, A. (2026) · Advanced Science · doi:10.1002/advs.76420 · Cited by 2
[Role of hyperglycemia-induced 5-hydroxytryptamine degradation of hepatic stellate cells in hepatic inflammation and fibrosis induced by type 2 diabetes mellitus].
Liang, X., Shan, X., Guan, J., Zhang, R., Yang, J., Zhang, Y., jin, J., Zhang, Y., Xu, F., & Fu, J. (2022) · PubMed Central · doi:10.19723/j.issn.1671-167x.2022.06.014 · Cited by 2
Spatial Transcriptomics Reveals the Transcriptomic Signatures in a Mouse Model of Pediatric Metabolic Dysfunction–Associated Steatohepatitis
Jiang, L., Xu, Q.-Y., Zhou, Y.-C., Xu, J., & Fan, J. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.08.008 · Cited by 2
Modelling human liver disease: from steatotic liver disease to MASH-HCC
Stoess, C., & Feldstein, A. E. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01054-z · Cited by 2
Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
Li, K., Wang, J., Dang, M., Ren, R., Fu, M., Wang, J., Zhang, Q., & Zhao, C. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100585 · Cited by 2
Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo
Hong, J. G., Trotman, J. C., Carbajal, Y., Dey, P., Glass, M., Sclar, V., Alter, I. L., Zhang, P., Wang, L., Chen, L., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000671 · Cited by 5
Self-citation
Ablation of Hepatocyte Derived‐ FGL1 Does Not Aggravate Metabolic Dysfunction‐Associated Steatotic Liver Disease
Personnaz, J., Cannizzo, L., Martin, C. M. P., Desquesnes, A., Sotin, M., DaSilva, J., Perrier, P., Guillou, H., & Kautz, L. (2025) · The FASEB Journal · doi:10.1096/fj.202501997r · Cited by 1
Jianpi-Huayu-Jiedu formula improves metabolic dysfunction-associated steatohepatitis through ameliorateing hepatic oxidative stress and lipid accumulation in vivo and in vitro
Wu, X., Chen, T., Zhang, Z., Wang, D., Zhou, K., Li, J., Xu, L., Meng, C., Pan, H., Huang, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1612726 · Cited by 2
Fat and exposure to 4-nitroquinoline-1-oxide causes histologic and inflammatory changes in murine livers
Pitstick, L. D., Góral, J., Schmelter, R. A., Fuja, C. M., Ciancio, M. J., Pytynia, M., Meyer, A., & Green, J. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268891 · Cited by 2
Experimental Workflow for Preclinical Studies of Human Antifibrotic Therapies
Reolizo, L., Matsuda, M., & Seki, E. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3207-9_18 · Cited by 2
Unaltered hepatic wound healing response in male rats with ancestral liver injury
Beil, J., Perner, J., Pfaller, L., Gérard, M.-A., Piaia, A., Doelemeyer, A., Naor, A. W., Martin, L., Piequet, A., Dubost, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41998-w · Cited by 3
Isogenic hiPSC-derived liver-on-chip platforms: A valuable tool for modeling metabolic liver diseases
Aina, K. O. (2023) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2023.100025 · Cited by 2
LipidSIM: Inferring mechanistic lipid biosynthesis perturbations from lipidomics with a flexible, low-parameter, Markov modeling framework
Liang, C., Murray, S., Li, Y., Lee, R. G., Low, A., Sasaki, S., Chiang, A. W. T., Lin, W.-J., Mathews, J. A., Barnes, W., et al. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2024.01.004 · Cited by 2
Effects of L-Ornithine L-Aspartate on the Physical Performance with Experimental Non-Alcoholic Fatty Liver Disease
Александровна, П. В., Poveryaeva, M. A., Sysoev, Y. I., Шустов, Е. Б., & Bunyat, A. V. (2020) · Journal Biomed · doi:10.33647/2074-5982-16-3-77-80 · Cited by 2
RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expressionPreprint
Wang, Y., Tai, Y., Way, G. W., Zeng, J., Zhao, D., Su, L., Jiang, X., Wang, X., Gurley, E. C., Liu, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1899177/v1 · Cited by 2
Therapeutic Activity of Resolvin D1 (RvD1) in Murine MASHPreprint
Navarro‐Corcuera, A., Zhu, Y., Ma, F., Gupta, N., Asplund, H., Yuan, F., Friedman, S., Sansbury, B. E., Huang, X. H., & Cai, B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.22.590633 · Cited by 2
Self-citation
Inhaled exposure to air fresheners aggravated liver injury in a murine model of nonalcoholic fatty acid liver disease
Kim, S., Lee, A. Y., & Cho, M. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06452 · Cited by 1
Diet, inflammation, and cancer
Chumanevich, A. A., Hébert, J. R., Spicer, M., & Hofseth, L. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822130-3.00016-8 · Cited by 1
Gene therapy as an innovative approach to the treatment of hemophilia B—a review
Wróblewska, K., Bieszczad, D., Popławska, M., Ziętara, K. J., Zajączkowska, M., & Filip, A. A. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00952-w · Cited by 1
Intestinal Activation of LXRα Counteracts Metabolic-Associated Steatohepatitis Features in Mice
Lioci, G., Gurrado, F., Panera, N., Bianchi, M., Stefanis, C. D., Doria, V., Cicolani, N., Santini, S. J., Schiadà, L., Alisi, A., et al. (2025) · Nutrients · doi:10.3390/nu17081349 · Cited by 1
Pyrimidinetrione benzodioxol ameliorates MAFLD-induced liver tumorigenesis and mood disorders in mice
Hsu, F.-Y., Chiu, W., Suk, F., Lee, C.-Y., Hsu, M.-H., & Liao, Y. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00023-1 · Cited by 1
Myeloid loss of scaffolding protein menin promotes liver fibrosis via H3K36me3 reprogramming
Han, Q., Chen, Y., Yuan, J.-B., Zhang, L., Zheng, Q., & Jin, G. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110471 · Cited by 1
AHR Deficiency Exacerbates Hepatic Cholesterol Accumulation via Inhibiting Bile Acid Synthesis in MAFLD Rats
Xu, J., Liu, P., Wu, Y., He, H., Hu, D., Sun, J., Chen, J., Tian, Y., & Gong, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010349 · Cited by 1
TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches
Callegari, E., Michilli, A., Moshiri, F., Siena, B. D., Gramantieri, L., Negrini, M., & Sabbioni, S. (2026) · BioTech · doi:10.3390/biotech15010009 · Cited by 1
SIRT1-mediated FABP4 destabilization attenuates fibrosis and ferroptosis in non-alcoholic fatty liver disease
Qiu, H., Chen, K., Qiu, Y., Yang, Y., Wang, T., Wang, W., & Jiang, L. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-02029-8 · Cited by 1
Roles of mitochondrial complexes in non-alcoholic fatty liver disease
Wang, K., Wang, L., Ning, J., & Li, D. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1752024 · Cited by 2
The NPC1/USP7/p53 axis regulates cholesterol and promotes the proliferation of hepatocellular carcinoma
Deng, R., Zheng, X., Liu, F., Gao, J., Wang, S., Yun, J., Wang, F., Li, Y., Ai, X., & Liu, Y. (2026) · Oncogene · doi:10.1038/s41388-026-03739-3 · Cited by 1
A subset of hepatic fibroblasts marked by Gli1 expression generates portal fibrosis and promotes ductular reaction
Raposo, M. A., Mourabit, H. E., Gao, W., Minini, M., Morichon, R., Fouassier, L., Wendum, D., Saad, M. J. A., dos Santos, A., Gautheron, J., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101819 · Cited by 3
Hepatic SEC16B regulates lipid homeostasis by coordinating VLDL secretion and lipid droplet expansion
Lu, W., Zhao, Z., Molina, D., Fan, H., Shi, R., Tian, Y., Gopoju, R., Yang, T., Zhang, X., Zhang, Y., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204602 · Cited by 1
Hepatocyte estrogen-related receptor α modulates a gluconeogenic–epigenetic crosstalk counteracting MASLD/MASH progression
Gao, J., Yang, M., Duan, R., Huang, T., Li, P., Gao, L., Lu, Z., Wong, C.-W., Geng, C., & Guan, M. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01707-1 · Cited by 1
Revisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughs
Zhu, L., & Wu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899587 · Cited by 1
ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion
Zhu, H., Huang, X., You, K., Chen, Y., Li, P., Tao, J., Yu, X., Jie-Hui, X., Xu, G., & Li, Y. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70496 · Cited by 1
Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics
Padvitski, T., Avila, P. U., Chen, H., Özel, C., Braun, F., Kroll, M.-K., Vossen, C., Wienand, P., Butt, L., Unnersjö‐Jess, D., et al. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101337 · Cited by 2
Zinc accumulation in macrophages exacerbates metabolic dysfunction-associated steatotic liver disease progression
Zhou, J., Wang, X., Liu, W., Yu, Y., Wang, S., Yao, Z., Song, Z., Shi, W., Zheng, W., Xie, E., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02816-z · Cited by 1
Review on the Role of Fructose in Non-Alcoholic Fatty Liver Diseases
Umaru, I. J., & Emmanuel, O. C. (2022) · International Journal of Scientific and Management Research · doi:10.37502/ijsmr.2022.5212 · Cited by 2
Glial cell derived neurotrophic factor prevents western diet and palmitate-induced hepatocyte oxidative damage and death through SIRT3
Mwangi, S. M., Li, G., Balasubramaniam, A., Merlin, D., Dawson, P. A., Jang, Y. C., Hart, C. M., Czaja, M. J., & Srinivasan, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-20101-1 · Cited by 2
Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
Ning, M., Song, L., Niu, X., Wang, Y., Liu, W., Hu, J., Cai, H., Song, W., Liu, L., Li, H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132452 · Cited by 2
A novel experimental mouse model of diabetic nonalcoholic steatohepatitis: A critical role for acid-sensitive Ion Channel 1a
Hu, X., Lin, H., Qian, S., Zhou, X., Li, Z., Qian, S., Yang, F., Hou, H., Xie, Q., Wu, W., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117184 · Cited by 2
Experimental models of fibrosis
Косолапов, В. А., Litvinov, R., & Спасов, А. А. (2024) · Journal of Volgograd State Medical University · doi:10.19163/1994-9480-2024-21-3-39-47 · Cited by 1
Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions
Jonscher, K. R., & Bruce, K. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12668-1_3 · Cited by 1
Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy
Reaume, A. G., & Lipinski, C. A. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839163401-00196 · Cited by 1
Accumulation of dihydrosphingolipids and neutral lipids is related to steatosis and fibrosis damage in human and animal models of non-alcoholic fatty liver diseasePreprint
Babiy, B., Ramos‐Molina, B., Ocaña, L., Sacristán, S., Burgos‐Santamaría, D., Martı́nez-Botas, J., Villa-Turégano, G., Busto, R., Perna, C., Frutos, M. D., et al. (2022) · medRxiv · doi:10.1101/2022.03.10.22271048 · Cited by 1
AATF-mediated Liver Damage and Inflammation to Cancer: Therapeutic Intervention by Curcumin in Experimental MASH-HCCPreprint
Srinivas, A. N., Suresh, D., Chidambaram, S. B., Santhekadur, P. K., & Kumar, D. P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.26.542402 · Cited by 1
Loss of cis-PTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinomaPreprint
Singh, A. K., Chaube, B., Citrin, K., Fowler, J. W., Lee, S., Catarino, J., Knight, J., Lowery, S. C., Shree, S., Boutagy, N., et al. (2023) · bioRxiv · doi:10.1101/2023.11.13.566870 · Cited by 1
Chiglitazar, the first pan-PPAR agonist approved globally, shows potential to treat metabolic dysfunction–associated steatohepatitis in vitro and in vivoPreprint
Deng, S., Li, S., Zhang, Q., Mao, X., Pan, D., Yang, X., & Huang, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4413947/v1 · Cited by 1
Targeting ZNRF3 and RNF43 to Restore Regeneration and Reverse Metabolic Dysfunction-Associated Steatotic Liver DiseasePreprint
Tullio, F. D., Yang, S. B., Yang, L., Cogliati, B., Roshan, S., Guo, K., Glezer, A., Conrad, J., Kumar, S. V., Almeida, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.19.660551 · Cited by 1
Novel Mechanism of Nonalcoholic Lipid Accumulation Promoting Malignant Transformation of Hepatocytes
Yao, M., Zheng, W., Wang, L., Fang, M., Dong, Z., & Yao, D. (2018) · InTech eBooks · doi:10.5772/intechopen.77400
Assessment of morpho-molecular inter-nodular heterogeneity in the primary and metastatic disease of patients with hepatocellular carcinoma
Filho, S. N. M. (2019) · doi:10.11606/t.5.2019.tde-04072019-083724
Влияние эмпаглифлозина и L-орнитина L-аспартата на поведенческо-когнитивные функции и физическую работоспособность при экспериментальном стеатогепатите
Александровна, П. В., Сысоев, Ю. И., Poveryaeva, M. A., Bunyat, A. V., Karev, V. E., Ивкин, Д. Ю., Суханов, Д. С., Шустов, Е. Б., & Оковитый, С. В. (2020) · Вестник Российского государственного медицинского университета · doi:10.24075/vrgmu.2020.034
A systematic analysis of rodent models implicates adipogenesis and innate immunity in pathogenesis of fatty liver diseasePreprint
Im, Y. R., Hunter, H., Hahn, D. D. G., Duret, A., Cheah, Q., Dong, J., Fairey, M., Hjalmarsson, C., Li, A., Lim, H. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.15.422799
What Is the Effect of Physical Exercise on Nafld/Nash
Ferreira, M. F. L., Caruso, Í. P., Fossey, M. A., Barbosa, W. F., & de Souza, F. P. (2021) · American Journal of Sports Science · doi:10.11648/j.ajss.20210901.11
Modelos animales de carcinoma hepatocelular y sus aplicaciones en biomedicina
de la Pisa, I. L. (2021) · Ambiociencias · doi:10.18002/ambioc.v0i18.6564
Effectiveness of Hepatoprotectors in the Practice of a Family Doctor
Zaremba, Y., Смалюх, О. В., & Zaremba, O. V. (2021) · Family Medicine · doi:10.30841/2307-5112.1.2021.231939

Authors: Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., & Friedman, S. L.
Affiliations: Tanabe Pharma Corporation (Japan) (JP)
Icahn School of Medicine at Mount Sinai (US)
Mount Sinai Hospital (US)
Corresponding author: Friedman, Scott L.
ORCID: Lee, Youngmin A.
Fujiwara, Naoto
Fiel, M. Isabel
Goossens, Nicolas
Hoshida, Yujin
Friedman, Scott L.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2018-08
Volume: 69
Issue: 2
Pages: 385-395
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2018.03.011
PMC: PMC6054570
OpenAlex: W2790198401
Cited by: 583
References: 56
Citations by year: 2026: 65 · 2025: 86 · 2024: 90 · 2023: 91 · 2022: 93 · 2021: 62 · 2020: 52 · 2019: 34 · 2018: 10
FWCI: 30.84
Type: journal article
Language: en
Update notices: erratum (2018-10-01)
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (am, 349 d)
Locations: Journal of Hepatology (acceptedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
HAL (submittedVersion)
Funders: NIH
NIDDK (DK099558)
European Commission (ERC-2014-AdG-671231)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, mouse model, Western diet, carbon tetrachloride, liver fibrosis, hepatocellular carcinoma, liver transcriptome, immune abnormalities, preclinical drug testing
MeSH terms: Animals, Carbon Tetrachloride, Disease Models, Animal, Fatty Liver, Inflammation, Liver Cirrhosis, Liver Neoplasms, Mice, Inbred C57BL, Reproducibility of Results, Disease Progression, Gene Expression Profiling, Mice, Diet, Western

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks